[go: up one dir, main page]

DK1888113T3 - Tweak-bindende antistoffer - Google Patents

Tweak-bindende antistoffer

Info

Publication number
DK1888113T3
DK1888113T3 DK06760258.1T DK06760258T DK1888113T3 DK 1888113 T3 DK1888113 T3 DK 1888113T3 DK 06760258 T DK06760258 T DK 06760258T DK 1888113 T3 DK1888113 T3 DK 1888113T3
Authority
DK
Denmark
Prior art keywords
binding antibodies
tweak binding
tweak
antibodies
binding
Prior art date
Application number
DK06760258.1T
Other languages
English (en)
Inventor
Linda C Burkly
Ellen Garber
Alexey Lugovskoy
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of DK1888113T3 publication Critical patent/DK1888113T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • General Engineering & Computer Science (AREA)
DK06760258.1T 2005-05-27 2006-05-25 Tweak-bindende antistoffer DK1888113T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68514905P 2005-05-27 2005-05-27
PCT/US2006/019706 WO2006130374A2 (en) 2005-05-27 2006-05-25 Tweak binding antibodies

Publications (1)

Publication Number Publication Date
DK1888113T3 true DK1888113T3 (da) 2014-09-01

Family

ID=37482143

Family Applications (2)

Application Number Title Priority Date Filing Date
DK11191771.2T DK2460831T3 (da) 2005-05-27 2006-05-25 Tweak-bindende antistoffer
DK06760258.1T DK1888113T3 (da) 2005-05-27 2006-05-25 Tweak-bindende antistoffer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK11191771.2T DK2460831T3 (da) 2005-05-27 2006-05-25 Tweak-bindende antistoffer

Country Status (29)

Country Link
US (2) US8048422B2 (da)
EP (3) EP2460832A3 (da)
JP (4) JP5175181B2 (da)
KR (2) KR20080023317A (da)
CN (3) CN101247830B (da)
AU (1) AU2006252830B2 (da)
BR (1) BRPI0611414B8 (da)
CA (1) CA2609600C (da)
CY (1) CY1118343T1 (da)
DK (2) DK2460831T3 (da)
EA (1) EA018255B1 (da)
ES (2) ES2507069T3 (da)
GE (1) GEP20115324B (da)
HU (1) HUE030701T2 (da)
IL (1) IL187585A (da)
IS (1) IS8693A (da)
LT (1) LT2460831T (da)
ME (2) ME00261B (da)
MX (1) MX339015B (da)
NO (1) NO20076607L (da)
NZ (2) NZ583636A (da)
PL (3) PL2460831T3 (da)
PT (2) PT1888113E (da)
RS (1) RS55888B1 (da)
SG (1) SG162728A1 (da)
SI (2) SI1888113T1 (da)
UA (1) UA96416C2 (da)
WO (1) WO2006130374A2 (da)
ZA (1) ZA200710765B (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
AU2507700A (en) * 1999-01-15 2000-08-01 Biogen, Inc. Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
SI1997512T1 (sl) * 2002-04-09 2014-03-31 Biogen Idec Ma Inc. Postopki za zdravljenje stanj, povezanih s TWEAK-om
WO2006052926A2 (en) * 2004-11-08 2006-05-18 University Of Maryland, Baltimore Tweak as a therapeutic target for treating central nervous system diseases associated with cerebral edema and and cell death
US7939490B2 (en) 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
WO2006088890A2 (en) * 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating stroke
DK2529619T3 (da) 2005-02-17 2016-01-11 Biogen Ma Inc Behandling af neurologiske sygdomme
CA2607697C (en) * 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2006130429A2 (en) * 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
WO2008048924A2 (en) * 2006-10-16 2008-04-24 Biogen Idec Ma Inc. Biomarkers of multiple sclerosis
US8685741B1 (en) * 2007-03-07 2014-04-01 Nestec S.A. Methods for diagnosing irritable bowel syndrome
CN102076355B (zh) 2008-04-29 2014-05-07 Abbvie公司 双重可变结构域免疫球蛋白及其用途
AU2009256246B2 (en) 2008-06-03 2013-07-18 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
SG191639A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AU2009268585C1 (en) 2008-07-08 2014-10-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
US8093006B2 (en) 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
KR20160005143A (ko) 2009-05-13 2016-01-13 젠자임 코포레이션 항-인간 ｃｄ52 면역글루불린
TW201119673A (en) * 2009-09-01 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY32948A (es) * 2009-10-15 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US9096879B2 (en) 2009-11-24 2015-08-04 Biogen Ma Inc. Method of supplementing culture media to prevent undesirable amino acid substitutions
WO2011097500A2 (en) 2010-02-04 2011-08-11 University Of Louisville Research Foundation, Inc. The tweak/fn14 system regulates skeletal muscle atrophy and regeneration
PE20130614A1 (es) * 2010-06-24 2013-07-01 Abbvie Inc Inmunoglobulinas con dominio variable dual y su uso
TW201206473A (en) 2010-08-03 2012-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CN103260639A (zh) 2010-08-26 2013-08-21 Abbvie公司 双重可变结构域免疫球蛋白及其用途
SG188605A1 (en) 2010-10-05 2013-04-30 Hoffmann La Roche Antibodies against human tweak and uses thereof
WO2013102042A2 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual specific binding proteins directed against il-13 and/or il-17
PE20142422A1 (es) 2012-04-05 2015-01-21 Hoffmann La Roche Anticuerpos biespecificos contra tweak humana e il 17 humana y usos de los mismos
HK1212359A1 (en) 2012-11-01 2016-06-10 Abbvie Inc. Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
JP2016522793A (ja) 2013-03-15 2016-08-04 アッヴィ・インコーポレイテッド ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質
AR095199A1 (es) * 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
JP2016000003A (ja) * 2013-04-19 2016-01-07 アステラス製薬株式会社 新規抗ヒトｔｗｅａｋ抗体
EP3052128A2 (en) 2013-10-04 2016-08-10 Biogen MA Inc. Tweak antagonists for treating lupus nephritis and muscle atrophy
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
MA47163A (fr) 2016-12-16 2019-11-06 Biogen Ma Inc Facteur 11 de différenciation de croissance activé protéolytiquement stabilisé
UA130009C2 (uk) 2018-05-07 2025-10-15 Генмаб А/С Спосіб лікування раку за допомогою комбінації антитіла до pd-1 і кон'югата антитіла до тканинного фактора і лікарського засобу
US12220570B2 (en) 2018-10-05 2025-02-11 Shifamed Holdings, Llc Intravascular blood pumps and methods of use
EA202191179A1 (ru) 2018-10-29 2021-09-09 Байоджен Ма Инк. Гуманизированные и стабилизированные варианты fc5 для улучшения транспорта через гематоэнцефалический барьер
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
JP7415939B2 (ja) * 2018-10-31 2024-01-17 アステラス製薬株式会社 抗ヒトＦｎ１４抗体
CN112778372B (zh) * 2019-11-11 2025-09-23 苏州泽璟生物制药股份有限公司 咪唑并喹啉取代磷酸酯类激动剂及其制备方法和应用
TW202302648A (zh) * 2021-03-12 2023-01-16 美商健生生物科技公司 Cd79b抗體於自體免疫治療應用之用途

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
EP1997891A1 (en) 1988-09-02 2008-12-03 Dyax Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AT396939B (de) * 1990-05-29 1993-12-27 Alois Dipl Ing Dr Jungbauer Komplexes virales antigen von hiv-1 bindendes rekombinantes protein
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5370901A (en) 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
ATE439435T1 (de) 1991-03-01 2009-08-15 Dyax Corp Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon
DE69233750D1 (de) 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
EP0590058B1 (en) * 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
EA003187B1 (ru) 1996-08-07 2003-02-27 Байоджен, Инк. Лиганд, родственный фактору некроза опухоли
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
JP2001513626A (ja) * 1997-02-12 2001-09-04 アボツト・ラボラトリーズ 疾患の治療及び診断のために有用なｔｎｆファミリーのメンバー
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
CA2305713A1 (en) 1997-10-10 1999-04-22 Genentech, Inc. Apo-3 ligand
JP2002527096A (ja) * 1998-10-16 2002-08-27 イミュネックス・コーポレーション 血小板の活性化及び補充の阻害剤
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
AU2507700A (en) * 1999-01-15 2000-08-01 Biogen, Inc. Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
US7309687B1 (en) * 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
AU782067B2 (en) * 1999-12-20 2005-06-30 Immunex Corporation TWEAK receptor
US7495086B2 (en) 1999-12-20 2009-02-24 Immunex Corporation TWEAK receptor
US6727225B2 (en) * 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
US6943146B2 (en) 2000-05-08 2005-09-13 Biogen Idec Ma Inc. Method for promoting neovascularization
US7208151B2 (en) * 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
CA2422095A1 (en) 2000-09-14 2002-03-21 Biogen, Inc. Tweak receptor agonists as anti-angiogenic agents
EP1430666B1 (en) 2001-09-27 2005-08-31 Matsushita Electric Industrial Co., Ltd. Transmission method, sending device and receiving device
SI1997512T1 (sl) * 2002-04-09 2014-03-31 Biogen Idec Ma Inc. Postopki za zdravljenje stanj, povezanih s TWEAK-om
EP1587540B1 (en) 2003-01-09 2021-09-15 MacroGenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
US20050079574A1 (en) 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
WO2004072266A2 (en) 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
ATE364050T1 (de) * 2003-07-24 2007-06-15 Amgen Inc Zusammensetzungen und verfahren, die multimere und oligomere lösliche fragmente des tweak- rezeptors betreffen
EP1566636A1 (en) 2004-02-23 2005-08-24 AXARON Bioscience AG Use of Tweak modulators and inhibitors for the treatment of neurological conditions
WO2006052926A2 (en) 2004-11-08 2006-05-18 University Of Maryland, Baltimore Tweak as a therapeutic target for treating central nervous system diseases associated with cerebral edema and and cell death
US7939490B2 (en) * 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
DK2529619T3 (da) * 2005-02-17 2016-01-11 Biogen Ma Inc Behandling af neurologiske sygdomme
WO2006088890A2 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating stroke
CN101171035A (zh) * 2005-03-07 2008-04-30 健泰科生物技术公司 用于调控tweak和fn14活性的方法和组合物
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2006130429A2 (en) * 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
WO2006138219A2 (en) * 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
WO2008048924A2 (en) 2006-10-16 2008-04-24 Biogen Idec Ma Inc. Biomarkers of multiple sclerosis

Also Published As

Publication number Publication date
BRPI0611414B1 (pt) 2019-04-16
KR20130140230A (ko) 2013-12-23
CN101247830A (zh) 2008-08-20
SI2460831T1 (sl) 2017-01-31
PT1888113E (pt) 2014-09-04
EP2460831A3 (en) 2012-10-31
CN101247830B (zh) 2013-03-27
EP1888113A4 (en) 2009-07-22
MX339015B (es) 2016-05-09
AU2006252830B2 (en) 2012-11-22
RS20070462A (sr) 2008-11-28
DK2460831T3 (da) 2016-12-19
KR101679468B1 (ko) 2016-11-24
LT2460831T (lt) 2016-12-12
WO2006130374A2 (en) 2006-12-07
CY1118343T1 (el) 2017-06-28
CA2609600A1 (en) 2006-12-07
JP5175181B2 (ja) 2013-04-03
JP2013040210A (ja) 2013-02-28
IL187585A (en) 2012-02-29
CA2609600C (en) 2016-11-08
US20120009178A1 (en) 2012-01-12
ME00261B (me) 2011-02-10
CN102441163A (zh) 2012-05-09
HK1169418A1 (en) 2013-01-25
WO2006130374A3 (en) 2007-12-13
IL187585A0 (en) 2008-04-13
US8048422B2 (en) 2011-11-01
SG162728A1 (en) 2010-07-29
HUE030701T2 (hu) 2017-05-29
UA96416C2 (uk) 2011-11-10
EP1888113B1 (en) 2014-06-25
IS8693A (is) 2007-11-29
PT2460831T (pt) 2017-01-17
KR20080023317A (ko) 2008-03-13
AU2006252830A1 (en) 2006-12-07
JP2014221837A (ja) 2014-11-27
PL2460831T3 (pl) 2017-05-31
NZ583636A (en) 2011-12-22
ES2507069T3 (es) 2014-10-14
JP2017025105A (ja) 2017-02-02
EP1888113A2 (en) 2008-02-20
HK1121072A1 (en) 2009-04-17
HK1116423A1 (en) 2008-12-24
PL1888113T3 (pl) 2014-11-28
ES2605945T3 (es) 2017-03-17
PL218791B1 (pl) 2015-01-30
ZA200710765B (en) 2009-09-30
EA200702643A1 (ru) 2008-04-28
EP2460831A2 (en) 2012-06-06
SI1888113T1 (sl) 2014-10-30
BRPI0611414A2 (pt) 2010-09-08
RS55888B1 (sr) 2017-08-31
NO20076607L (no) 2008-02-27
EP2460832A3 (en) 2012-10-31
MEP35408A (en) 2011-02-10
EA018255B1 (ru) 2013-06-28
EP2460831B1 (en) 2016-10-19
EP2460832A2 (en) 2012-06-06
GEP20115324B (en) 2011-11-10
JP6234535B2 (ja) 2017-11-22
JP2008542278A (ja) 2008-11-27
CN103242447B (zh) 2016-04-27
US20080241163A1 (en) 2008-10-02
NZ564092A (en) 2010-05-28
CN103242447A (zh) 2013-08-14
BRPI0611414B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
NO20201120A1 (no) Bindingsvirkninger
DK1888113T3 (da) Tweak-bindende antistoffer
HRP20150176T1 (xx) Protutijela protiv miostatina
DK1964852T3 (da) Anti-ilt7-antistof
DK1864998T3 (da) Bindingsmolekyler
NO20071430L (no) Anti-OX4OL antistoffer
DE602006012066D1 (de) Daraus
EP1839669A4 (en) NEW ANGIOGENESIS INHIBITOR
NO20052035D0 (no) Stopemasse
EP1932681A4 (en) LEVER ARCH FILES
DE502006000473D1 (de) Heftklammergerät
FI20050547A0 (fi) Side
DK1931573T3 (da) Lukke
FI20050927A0 (fi) Sidontalaite
FI20050349A0 (fi) Sidontalaite
FI20050718A0 (fi) Sidontalaite
FI20050009A0 (fi) Sidontalaite
FIU20050104U0 (fi) Mäkihyppyside
FI20050348A0 (fi) Sidontaverkko
FI20041026A0 (fi) Sidontalaite
FI20050725A0 (fi) Sideaine
FI20041350A0 (fi) Sidontalaite
UA12696S (uk) Книга
UA12402S (uk) Буклет
DE602006017867D1 (de) Heftgerät